Breast Cancer: Drugs

(asked on 30th April 2018) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential effect of the UK leaving the European Medicines Agency on patients' ability to access breast cancer drugs.


Answered by
Jackie Doyle-Price Portrait
Jackie Doyle-Price
This question was answered on 9th May 2018

From 30 March 2019, the United Kingdom will no longer be a Member of the European Union. However, under the terms of the implementation period agreement regulatory standards and market access for all medicines, will continue on current terms.

Regarding the future relationship, the Prime Minister's Mansion House speech outlined that we will also explore the terms on which the UK could remain part of the European Medicines Agency. While it would not be appropriate to pre-judge the outcome of the negotiations, we will discuss with the EU and Member States how best to continue cooperation in medicines regulation.

Our overall aim is to ensure that patients in the UK and across the EU continue to be able to access the best and most innovative medicines, including breast cancer drugs, and be assured that their safety is protected through the strongest regulatory framework and continued sharing of data.

Reticulating Splines